Routine Inpatient Mobility Assessment and Hospital Discharge Planning
Patient mobility is an indicator of health and a predictor associated with clinical outcomes. However, mobility status is not routinely measured in hospitalized patients.
1 Consequently, physicians do not recognize when patients experience low baseline mobility and declines in mobility status during hospitalization.
2
Hospitalized patients with impaired mobility often require discharge to a postacute facility. Because physicians do not recognize impaired mobility until after resolution of acute medical or surgical issues, engagement with physical therapists, case managers, and social workers needed for placement is often delayed. Routinely measuring mobility status of inpatients may help facilitate postdischarge planning. 4 Hence, we sought to evaluate whether a simple validated mobility assessment tool, completed by nurses as part of routine clinical care, is associated with discharge to a postacute facility.
Methods | We conducted a retrospective cohort study on data from 2876 consecutive patients admitted from January 1, 2015, to January 1, 2016, on 2 inpatient units (medical and neurological and/or neurosurgical) at The Johns Hopkins Hospital. Data were obtained from the electronic medical record and the hospital's administrative database used for statewide reporting. The Johns Hopkins Institutional Review Board approved this study with a waiver of consent based on retrospective analysis of deidentified data. Data were analyzed from January 1, 2018, to May 1, 2018. For all patients, mobility status (primary exposure) was measured by nurses as part of routine clinical care on the day of hospital admission and 3 times weekly, using the Activity Measure for Post-Acute Care Inpatient Mobility Short Form (AM-PAC IMSF). This reliable and valid tool consists of 6 items indicating the level of assistance required to perform mobility tasks, with standardized scores ranging from a low of 23.55 to a high of 61.14.
5
Mobility status at hospital admission was evaluated in 2 ways: by tertile and by a 10-point (1-SD) difference in the AM-PAC IMSF score. Admission mobility status is reported according to tertile of the AM-PAC IMSF standardized scale score (low: 23.55-39.45; middle: 40.78-45.44; high: 47.67-61. 14 [lower scores are associated with higher odds for facility placement]). Change in mobility status during hospitalization was calculated as the difference between discharge and admission scores, with patients dichotomized as declined vs no change or improved, with associated statistical analyses accounting for admission mobility status along with other covariates (detailed in the methods for the multivariable regression analysis).
The primary outcome was discharge to a health care facility (including inpatient rehabilitation or skilled nursing).
Multivariable logistic regression analysis was used to separately evaluate the associations of admission patient mobility status and change in mobility status with the health care facility disposition, adjusting for age, sex, race/ ethnicity, payer, primary diagnoses, and Agency for Healthcare Research and Quality Elixhauser comorbidity index. Data analyses were performed using statistical software (SAS, version 9.4; SAS Institute Inc), and statistical significance was defined as 2-sided P < .05.
Results | Mobility scores were completed at admission and discharge for more than 95% of patients. Among 2876 patients, 716 (25%) were discharged to a facility (Table) .
Patient mobility score at hospital admission was independently associated with facility placement, with adjusted odds ratios (aOR) for facility placement of 3.1 (95% CI, 2.8-3.6; P < .001) for a 10-point negative difference in AM-PAC IMSF, and 9.8 (95% CI, 7.3-13.2; P < .001) for comparison of lowest vs highest tertile of mobility score and 2.5 (95% CI, 1.8-3.4; P < .001) for comparison of middle tertiles vs highest tertile of mobility score.
For patients whose mobility score declined (vs no change or improved), after adjustment for mobility score at admission and all covariates, the aOR for facility placement was 3.6 (95% CI, 2.7-4.9; P < .001).
Discussion | A validated measure of patient mobility, routinely collected by nurses as part of clinical care, appears to be associated with discharge placement. Recognition of low mobility scores at admission or declining mobility status during hospitalization should prompt early engagement of physical therapists, case managers, and social workers to address issues of patient mobility and facility placement. Additionally, recognition of high mobility scores may allow physicians to choose wisely and decrease low-value physical therapy consults to reallocate this scarce resource to patients who may achieve greater benefit. (8) 246 (11) Diagnostic category for hospitalization
Craniofacial surgery 1044 (36) 187 (26) 857 (40) Spinal surgery 797 (28) 186 (26) 611 (28) Medical 688 (24) 178 (25) 510 (24) Stroke or traumatic brain injury 224 (8) 130 (18) 94 (4) Other neurological diagnosis 123 (4) 35 (5) 88 (4) Elixhauser comorbidity index, mean (SD) 2. The implicit idea that naïve, pregnant, cannabis-using women require education is pejorative and paternalistic. Perhaps these women recognize that with no federal standing, quality medical research cannot be conducted on cannabis. Gold-standard randomized clinical trials are effectively illegal. What data we do have on cannabis does not show definitive harm.
Furthermore, the statement that women with NVP should be directed to conventional medications for NVP that are "effective and safe" ignores that some of the pharmacologic options have unknown effects in pregnant women. Remember thalidomide? It is no wonder the American College of Obstetricians and Gynecologists algorithm for NVP comes with the warning, "Some antiemetic medications have only been approved by the US Food and Drug Administration for use in nonpregnant patients; however, off-label use is common." 4(e20) In spite of our own biases as physicians, we must acknowledge that women may be knowingly choosing cannabis over conventional medications for several reasons. We must also recognize that women may be electing to use cannabis as the lesser evil or doing so to preserve sobriety from other bona fide, harmful substances such as alcohol or opioids. 5 Moreover, treating women who use cannabis like criminals could have negative repercussions if they forgo the prenatal care known to improve fetal-maternal outcomes.
We suggest that rather than taking a paternalistic approach to pregnant women, physicians support the health of the mother-to-be-including what works for her to remedy NVP. Dialog with pregnant patients and inquire why they are using cannabis to gain a better understanding. Then discuss the risks and benefits of cannabis compared with other treatment modalities in a nonjudgmental and unbiased way. In order for physicians to support women, they must educate themselves about cannabis as an alternative treatment approach and push for quality medical research for NVP.
